Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS2R38 | P59533 | 1/20 | 0.60 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 3/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | CTSV | O60911 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | TUBB | P07437 | 1/20 | 0.48 |
| ▸ | CTSL | P07711 | 1/20 | 0.48 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.48 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.48 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.48 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19955621 | 0.89 | ALDH1A1 (0.52) | TAS2R38NOTUMKDM4EGAAMAPT | |
| SCHEMBL8987066 | 0.89 | HPGD (0.51) | TAS2R38NOTUMKDM4EGAAMAPT | |
| SCHEMBL8987070 | 0.89 | CTSV (0.51) | TAS2R38NOTUMKDM4EGAAMAPT | |
| SCHEMBL8799713 | 0.89 | HPGD (0.51) | TAS2R38NOTUMKDM4EGAAMAPT | |
| SCHEMBL6762114 | 0.89 | CTSV (0.51) | TAS2R38NOTUMKDM4EGAAMAPT | |
| SCHEMBL8987106 | 0.89 | CYP1A2 (0.52) | TAS2R38NOTUMKDM4EGAAMAPT | |
| SCHEMBL8987311 | 0.89 | CYP1A2 (0.52) | TAS2R38NOTUMKDM4EGAAMAPT | |
| SCHEMBL8987193 | 0.86 | CYP19A1 (0.53) | TAS2R38NOTUMKDM4EGAAMAPT | |
| SCHEMBL8987203 | 0.85 | KIF11 (0.56) | TAS2R38NOTUMKDM4EGAAMAPT | |
| SCHEMBL8986985 | 0.85 | KDM4E (0.59) | KDM4EMAPTTDP1GPR84HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190044076-A1 | HETEROCYCLIC COMPOUND AND ORGANIC ELECTROLUMINESCENCE DEVICE INCLUDING THE SAME | SAMSUNG DISPLAY CO., LTD. (KR) | 2019-02-07 | — | — | US | disclosed |
| EP-3016169-B1 | ORGANIC OPTOELECTRIC DEVICE AND DISPLAY DEVICE | SAMSUNG SDI CO LTD (KR) | 2017-01-11 | — | — | EP | disclosed |
| US-20160354375-A1 | CASEIN KINASE 1delta (CK 1delta) INHIBITORS AND THEIR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES SUCH AS TAUOPATHIES | ELECTROPHORETICS LIMITED (GB) | 2016-12-08 | — | — | US | disclosed |
| WO-2016068460-A1 | ORGANIC OPTOELECTRONIC ELEMENT AND DISPLAY DEVICE | 삼성에스디아이 주식회사 | 2016-05-06 | — | — | WO | disclosed |
| WO-2016068446-A1 | ORGANIC OPTOELECTRONIC DIODE AND DISPLAY DEVICE | 삼성에스디아이 주식회사 | 2016-05-06 | — | — | WO | disclosed |
| US-20160126471-A1 | ORGANIC OPTOELECTRIC DEVICE AND DISPLAY DEVICE | SAMSUNG SDI CO., LTD. (KR) | 2016-05-05 | — | — | US | disclosed |
| US-20160126471-A1 | ORGANIC OPTOELECTRIC DEVICE AND DISPLAY DEVICE | SAMSUNG SDI CO., LTD. (KR) | 2016-05-05 | — | — | US | disclosed |
| EP-3016169-A1 | ORGANIC OPTOELECTRIC DEVICE AND DISPLAY DEVICE | Samsung SDI Co., Ltd. (KR) | 2016-05-04 | — | — | EP | disclosed |
| US-9136481-B2 | Compound for an organic photoelectric device, organic photoelectric device including the same, and display device including the organic photoelectric device | CHEIL INDUSTRIES, INC. (KR) | 2015-09-15 | — | — | US | disclosed |
| US-9136481-B2 | Compound for an organic photoelectric device, organic photoelectric device including the same, and display device including the organic photoelectric device | CHEIL INDUSTRIES, INC. (KR) | 2015-09-15 | — | — | US | disclosed |
| WO-2002036173-A2 | SIMULTANEOUS DUAL ISOTOPE IMAGING OF CARDIAC PERFUSION AND CARDIAC INFLAMMATION | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2002-05-10 | — | — | WO | disclosed |
| EP-0999856-A2 | RADIOPHARMACEUTICALS FOR IMAGING INFECTION AND INFLAMMATION | Du Pont Pharmaceuticals Company (US) | 2000-05-17 | — | — | EP | disclosed |
| CN-1239895-A | Radiopharmaceuticals for imaging sites of infection and inflammation | DU PONT MERCK PHARMA (US) | 1999-12-29 | — | — | CN | disclosed |
| WO-1998015295-A2 | RADIOPHARMACEUTICALS FOR IMAGING INFECTION AND INFLAMMATION | DUPONT PHARMACEUTICALS COMPANY (US) | 1998-04-16 | — | — | WO | disclosed |
| EP-0755381-A1 | SUBSTITUTED PYRIDINE LEUKOTRIENE B 4 ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 1997-01-29 | — | — | EP | disclosed |
| US-5492915-A | ANTIINFLAMMATORY AGENTS | RHONE-POULENC RORER S.A. (FR) | 1996-02-20 | — | — | US | disclosed |
| WO-1995028386-A1 | SUBSTITUTED PYRIDINE LEUKOTRIENE B4 ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 1995-10-26 | — | — | WO | disclosed |
| US-5366982-A | Antiinflammatory agents or antihistamines | RHONE-POULENC RORER S.A. (FR) | 1994-11-22 | — | — | US | disclosed |
| EP-0540604-A1 | SUBSTITUTED BICYCLIC BIS-ARYL COMPOUNDS EXHIBITING SELECTIVE LEUKOTRIENE B 4? ANTAGONIST ACTIVITY, THEIR PREPARATION AND USE IN PHARMACEUTICAL COMPOSITIONS | Aventis Pharma S.A. (FR) | 1993-05-12 | — | — | EP | disclosed |
| WO-1992001675-A2 | SUBSTITUTED BICYCLIC BIS-ARYL COMPOUNDS EXHIBITING SELECTIVE LEUKOTRIENE B4 ANTAGONIST ACTIVITY, THEIR PREPARATION AND USE IN PHARMACEUTICAL COMPOSITIONS | RHONE-POULENC RORER S.A. (FR) | 1992-02-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190044076-A1 | HETEROCYCLIC COMPOUND AND ORGANIC ELECTROLUMINESCENCE DEVICE INCLUDING THE SAME | OR10J3, RER1, ORC3 | TAS2R38 299/4885NOTUM 1543/4885KDM4E 2449/4885 |
| US-20160354375-A1 | CASEIN KINASE 1delta (CK 1delta) INHIBITORS AND THEIR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES SUCH AS TAUOPATHIES | CSNK1G1, CSNK1A1, CSNK1D | TAS2R38 4678/4885NOTUM 2040/4885KDM4E 1514/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.